Communiqués bioAffinity Technologies, Inc.

Actions

BIAF

US09076W4069

Equipement, fournitures et distribution médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Pré-ouverture 11:53:58
6,055 ^USD	-1,46%		6,195	+2,31%

30/09	Bioaffinity Technologies, Inc. et AvMEDICAL sensibilisent les anciens combattants et facilitent leur accès au test non invasif CyPath Lung de détection du cancer du poumon grâce à un partenariat de distribution	CI
22/09	BioAffinity Technologies, Inc. présente des données cliniques et axées sur les vétérans sur CyPath Lung lors de la conférence annuelle NAVREF 2026	CI

Communiqués

01/10	BioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL	AQ
30/09	BioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL	BU
22/09	BioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference	BU
18/09	BioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath(R) Lung Noninvasive Lung Cancer Diagnostic	AQ
17/09	BioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic	BU
09/09	BioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements	BU
03/09	BioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference	BU
02/09	BioAffinity Technologies Advances CyPath(R) Lung for Surveillance of Lung Cancer Survivors	AQ
02/09	Catalysts Emerge BIAF, LIDR, SSM, GMGMF to Watch Now	AQ
01/09	BioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors	BU
20/08	BioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026	BU
19/08	BioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath Lung	AQ
18/08	BioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung	BU
17/08	BioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules	AQ
14/08	BioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules	BU
13/08	BioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules	BU
07/08	BioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung	BU
28/07	BioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath Lung	AQ
27/07	BioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung	BU
23/07	BioAffinity Technologies and Pictor, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD	AQ
22/07	BioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD	BU
07/07	BioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues	BU
22/06	BioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells	BU
18/06	BioAffinity Technologies Announces Closing of $3.2 Million Offering	BU
17/06	WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering	PR